Septerna, Inc. (NASDAQ:SEPN) Receives $43.13 Average Price Target from Analysts

Septerna, Inc. (NASDAQ:SEPN) has received an average recommendation of “Moderate Buy” from the eleven research firms that are covering the firm, MarketBeat reports. One investment analyst has rated the stock with a sell recommendation, one has given a hold recommendation, seven have given a buy recommendation and two have assigned a strong buy recommendation to the company. The average 1 year target price among analysts that have issued a report on the stock in the last year is $45.7778.

A number of research firms have issued reports on SEPN. Weiss Ratings reissued a “sell (d-)” rating on shares of Septerna in a research report on Tuesday, April 21st. Zacks Research raised shares of Septerna from a “strong sell” rating to a “hold” rating in a research report on Tuesday, February 24th. Truist Financial raised their price target on shares of Septerna from $34.00 to $35.00 and gave the stock a “buy” rating in a research report on Wednesday, March 11th. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $60.00 target price on shares of Septerna in a report on Tuesday, March 10th. Finally, Raymond James Financial lifted their target price on shares of Septerna from $47.00 to $53.00 and gave the company a “strong-buy” rating in a report on Monday.

Septerna Trading Up 5.6%

SEPN opened at $35.95 on Monday. Septerna has a 12-month low of $9.85 and a 12-month high of $36.26. The firm has a market capitalization of $1.62 billion, a PE ratio of -44.38 and a beta of 2.39. The firm has a 50 day moving average of $26.98 and a two-hundred day moving average of $26.79.

Septerna (NASDAQ:SEPN) last posted its quarterly earnings results on Tuesday, May 12th. The company reported ($0.19) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.42) by $0.23. Septerna had a negative net margin of 49.88% and a negative return on equity of 12.72%. The company had revenue of $26.52 million during the quarter, compared to analyst estimates of $16.98 million. As a group, analysts predict that Septerna will post -1.57 EPS for the current fiscal year.

Insider Activity at Septerna

In other news, COO Elizabeth Bhatt sold 4,000 shares of Septerna stock in a transaction that occurred on Wednesday, April 15th. The shares were sold at an average price of $24.34, for a total transaction of $97,360.00. Following the completion of the transaction, the chief operating officer directly owned 174,209 shares of the company’s stock, valued at $4,240,247.06. The trade was a 2.24% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Samira Shaikhly sold 11,798 shares of the business’s stock in a transaction on Tuesday, May 26th. The stock was sold at an average price of $30.06, for a total transaction of $354,647.88. Following the completion of the sale, the insider directly owned 793 shares of the company’s stock, valued at approximately $23,837.58. The trade was a 93.70% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders have sold 21,733 shares of company stock valued at $623,707. Insiders own 4.30% of the company’s stock.

Institutional Investors Weigh In On Septerna

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. Janus Henderson Group PLC acquired a new stake in Septerna during the 1st quarter worth $21,334,000. First Light Asset Management LLC boosted its position in shares of Septerna by 18.0% during the 1st quarter. First Light Asset Management LLC now owns 732,860 shares of the company’s stock valued at $17,611,000 after acquiring an additional 112,049 shares during the last quarter. Renaissance Technologies LLC acquired a new position in shares of Septerna during the 1st quarter valued at about $906,000. Swiss National Bank acquired a new position in shares of Septerna during the 1st quarter valued at about $531,000. Finally, Bank of New York Mellon Corp boosted its position in shares of Septerna by 6.1% during the 1st quarter. Bank of New York Mellon Corp now owns 58,709 shares of the company’s stock valued at $1,411,000 after acquiring an additional 3,377 shares during the last quarter.

About Septerna

We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases. GPCRs are the largest and most diverse family of cell membrane receptors and regulate physiological processes in nearly every organ system of the human body.